Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma

NCT01339975 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT01339975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01339975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma
Lead sponsor
University Hospital, Bordeaux
Phase
Observational
Overall status
Completed
Start date
June 6, 2011
Completion date
May 31, 2019
Enrollment
310 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, carcinoma renal cell, chemokines, kidney diseases, kidney neoplasms